Experienced in Polymorphous Low Grade Adenocarcinoma

Dr. Michael K. Gibson

Oncology
Vanderbilt Health Clinicians, LLC
3601 The Vanderbilt Clinic, 
Nashville, TN 
Accepting New Patients
Offers Telehealth
Experienced in Polymorphous Low Grade Adenocarcinoma
Vanderbilt Health Clinicians, LLC
3601 The Vanderbilt Clinic, 
Nashville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Gibson is an Oncologist in Nashville, Tennessee. Dr. Gibson is rated as an Experienced provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Adenoid Cystic Carcinoma, Percutaneous Coronary Intervention (PCI), and Gastrostomy. Dr. Gibson is currently accepting new patients.

His clinical research consists of co-authoring 83 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in TN
Hospital Affiliations
Vanderbilt University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

VANDERBILT HEALTH CLINICIANS, LLC
3601 The Vanderbilt Clinic, Nashville, TN 37232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
An Open-label, Phase 1, Dose-escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 With Pembrolizumab Following Radiation Therapy in the Treatment of Non-small-cell Lung Cancer, Triple-negative Breast Cancer, or Squamous-cell Carcinoma of the Head and Neck That Has Progressed on Checkpoint Inhibitors
An Open-label, Phase 1, Dose-escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 With Pembrolizumab Following Radiation Therapy in the Treatment of Non-small-cell Lung Cancer, Triple-negative Breast Cancer, or Squamous-cell Carcinoma of the Head and Neck That Has Progressed on Checkpoint Inhibitors
Enrollment Status: Completed
Publish Date: September 04, 2025
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, TAK-676
Study Phase: Phase 1
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 19, 2025
Intervention Type: Combination product, Biological
Study Drugs: Pembrolizumab, Cemiplimab
Study Phase: Phase 1/Phase 2
Multimodality Therapy With Induction Carboplatin/Nab-Paclitaxel/Durvalumab Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck
Multimodality Therapy With Induction Carboplatin/Nab-Paclitaxel/Durvalumab Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Active_not_recruiting
Publish Date: February 07, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Durvalumab, Carboplatin, Nab-Paclitaxel, Cisplatin
Study Phase: Phase 2
A Phase Ib Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN)
A Phase Ib Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN)
Enrollment Status: Withdrawn
Publish Date: November 30, 2023
Intervention Type: Radiation, Drug
Study Drugs: Zimberelimab, Etrumadenant, Cisplatin
Study Phase: Phase 1
Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation
Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation
Enrollment Status: Terminated
Publish Date: October 11, 2023
Intervention Type: Radiation, Drug
Study Phase: Phase 2
Phase 1 and Phase 2a, First-in-human Study of DRP-104, a Glutamine Antagonist, in Adult Patients With Advanced Solid Tumors
Phase 1 and Phase 2a, First-in-human Study of DRP-104, a Glutamine Antagonist, in Adult Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: June 12, 2023
Intervention Type: Biological, Drug
Study Drugs: DRP-104, Atezolizumab
Study Phase: Phase 1/Phase 2
Phase II Study of Stereotactic Radiosurgery for Patients With Oligo-recurrent Disease
Phase II Study of Stereotactic Radiosurgery for Patients With Oligo-recurrent Disease
Enrollment Status: Completed
Publish Date: May 19, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: April 03, 2023
Intervention Type: Drug
Study Drugs: CDX-3379, Cetuximab
Study Phase: Phase 2
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
Enrollment Status: Terminated
Publish Date: January 03, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Pilot Study of ADP-A2M4 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Cancer
A Phase 2 Pilot Study of ADP-A2M4 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Cancer
Enrollment Status: Withdrawn
Publish Date: November 16, 2021
Intervention Type: Genetic
Study Phase: Phase 2
A Multi-Center Open Label Single Arm Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
A Multi-Center Open Label Single Arm Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials
Similar Doctors
Distinguished in Polymorphous Low Grade Adenocarcinoma
Dr. Jill Gilbert
Hematology Oncology | Hematology | Oncology
Distinguished in Polymorphous Low Grade Adenocarcinoma
Dr. Jill Gilbert
Hematology Oncology | Hematology | Oncology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (0.1 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jill Gilbert is a Hematologist Oncology specialist and a Hematologist in Nashville, Tennessee. Dr. Gilbert is rated as a Distinguished provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. Her top areas of expertise are Follicular Thyroid Cancer, Thyroid Cancer, Polymorphous Low Grade Adenocarcinoma, and Papillary Thyroid Cancer. Dr. Gilbert is currently accepting new patients.

Experienced in Polymorphous Low Grade Adenocarcinoma
Dr. Jennifer H. Choe
Oncology | Hematology Oncology
Experienced in Polymorphous Low Grade Adenocarcinoma
Dr. Jennifer H. Choe
Oncology | Hematology Oncology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (0.1 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jennifer Choe is an Oncologist and a Hematologist Oncology provider in Nashville, Tennessee. Dr. Choe is rated as an Advanced provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. Her top areas of expertise are Anaplastic Thyroid Cancer, Thyroid Cancer, Adenoid Cystic Carcinoma, and Follicular Thyroid Cancer. Dr. Choe is currently accepting new patients.

Experienced in Polymorphous Low Grade Adenocarcinoma
Dr. Jeff Russell
Hematology | Oncology
Experienced in Polymorphous Low Grade Adenocarcinoma
Dr. Jeff Russell
Hematology | Oncology

Tennessee Oncology PLLC

250 25th Ave N, Suite 100, 
Nashville, TN 
 (1.1 miles away)
615-320-5090
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeff Russell is a Hematologist and an Oncologist in Nashville, Tennessee. Dr. Russell is rated as an Advanced provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Merkel Cell Carcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), and Tongue Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gibson's expertise for a condition
ConditionClose
    View All 41 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile